Dropropizine
Dropropizine ((±) -Dropropizine; UCB-196) is an orally effective, peripherally selective antitussive that inhibits the activity of peripheral receptors and afferent nerves in the respiratory tract. Dropropizine acts on the cough reflex pathway, does not pass the blood-brain barrier, and has no central nervous system side effects. Dropropizine mainly regulates the level of sensory neuropeptides and inhibits the afferent signal transmission of the cough reflex, thereby alleviating the symptoms of dry cough, and has both mild local anesthetic and antihistamine activity. Dropropizine is mainly used for symptomatic research on dry cough caused by respiratory diseases[1].
Product Specifications
CAS Number
[17692-31-8]
Product Name Alternative
(±) -Dropropizine; UCB-196
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Others
Type
Reference compound
Related Pathways
Others
Applications
COVID-19-immunoregulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/Dropropizine.html
Purity
99.32
Solubility
DMSO : ≥ 41 mg/mL|H2O : ≥ 33.33 mg/mL
Smiles
OCC(O)CN1CCN(C2=CC=CC=C2)CC1
Molecular Formula
C13H20N2O2
Molecular Weight
236.31
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Explore Other Products
Browse additional items from our catalog
MELK (Maternal Embryonic Leucine Zipper Kinase) BioAssayTM ELISA Kit (Human) discontinued
MELK (Maternal Embryonic Leucine Zipper Kinase) BioAssayTM ELISA Kit (Human) discontinued
NFkB, p50 (NF-kB, Nuclear Factor kappa B p50 Subunit, Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B cells 1, NFkB1, DKFZp686C01211, DNA Binding Factor KBF1, EBP-1, KBF1, MGC54151, NF-kappa-B, NF-kB, Nuclear Factor kappa B DNA Binding Subunit)